These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20972591)

  • 1. Tuberculosis and anti-TNF treatment: experience of a central London hospital.
    Mankia S; Peters JE; Kang S; Moore S; Ehrenstein MR
    Clin Rheumatol; 2011 Mar; 30(3):399-401. PubMed ID: 20972591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
    Tubach F; Salmon D; Ravaud P; Allanore Y; Goupille P; Bréban M; Pallot-Prades B; Pouplin S; Sacchi A; Chichemanian RM; Bretagne S; Emilie D; Lemann M; Lortholary O; Mariette X;
    Arthritis Rheum; 2009 Jul; 60(7):1884-94. PubMed ID: 19565495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etanercept therapy in patients with a positive tuberculin skin test.
    Manadan AM; Joyce K; Sequeira W; Block JA
    Clin Exp Rheumatol; 2007; 25(5):743-5. PubMed ID: 18078624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
    Dixon WG; Hyrich KL; Watson KD; Lunt M; Galloway J; Ustianowski A; ; Symmons DP;
    Ann Rheum Dis; 2010 Mar; 69(3):522-8. PubMed ID: 19854715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():47-55. PubMed ID: 24789000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Etanercept and infection - latent tuberculosis].
    González-Sixto B; Rodríguez-Prieto MA
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():62-9. PubMed ID: 20492883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.
    Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA
    J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
    Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment.
    Sartori NS; Picon P; Papke A; Neyeloff JL; da Silva Chakr RM
    PLoS One; 2019; 14(12):e0224963. PubMed ID: 31790428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.
    Kisacik B; Pamuk ON; Onat AM; Erer SB; Hatemi G; Ozguler Y; Pehlivan Y; Kilic L; Ertenli I; Can M; Direskeneli H; Keser G; Oksel F; Dalkilic E; Yilmaz S; Pay S; Balkarli A; Cobankara V; Cetin GY; Sayarlioglu M; Cefle A; Yazici A; Avci AB; Terzioglu E; Ozbek S; Akar S; Gul A
    J Rheumatol; 2016 Mar; 43(3):524-9. PubMed ID: 26773107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis].
    Xie X; Chen J; Peng Y; Gao J; Tian J; Ling G; Du J; Mao N; Wu P; Li F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 38(7):722-36. PubMed ID: 23908082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy.
    Ringrose JS; Sanche SE; Taylor-Gjevre RM
    Clin Exp Rheumatol; 2011; 29(5):790-4. PubMed ID: 21961892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.